Home / People / Vsevolod Tyupa
Portrait of Vsevolod Tyupa

Vsevolod Tyupa

Head of Life Sciences & Healthcare

Naberezhnaya Tower 10C
123112 Moscow
Languages English, Russian

Vsevolod Tyupa is Counsel and Head of Life Sciences & Healthcare sector group. 

Vsevolod is a legal counsel of many international and Russian companies on the entry into and operating on the Russian pharmaceutical and medical device markets. Vsevolod advises on regulatory and commercial matters, contracts conclusion, compliance matters, anticorruption and competition issues, legal aspects of clinical trials, promotion of medical products and interactions with HCPs and HCOs, public procurement and personal data issues. Besides legal regulation of the Life Sciences sector, Vsevolod specialises in commercial law, regulatory requirements, compliance, legislation on personal data, public procurement.

Before joining the firm in 2011, Vsevolod worked for Roche as head of the legal department and compliance officer. 

more less

Practice head Vsevolod Tyupa is well-regarded for his expertise in the sector. "He has practical experience of working with many healthcare companies; he really understands how such companies work," a client reports.

Chambers Europe

Relevant experience

  • Gilead Sciences – leading external advisor on all key projects of the company starting from the entry into the Russian market in 2013. Provides legal support of the product localization projects, regulatory advice, routine day-to-day legal support. Represents the client in public authorities.
  • GE Healthcare – successfully defended the client’s interests in the court of appeal and further in the court of cassation against the Russian healthcare regulatory authority (Roszdravnadzor). Invalidated the regulator’s refusal from registering one of GE Healthcare products, a modern ultrasound diagnostic system, in Russia.
  • Johnson & Johnson – regular advice on compliance and regulatory matters, including product liability, licensing issues, labelling and packaging, interactions with HCPs and public authorities.
  • Zentiva – advising the global investment company Advent International and its group company Zentiva on the acquisition of the CEE business of Alvogen, a global manufacturer of generics and over-the-counter drugs.
  • Roche Diabetes Care Rus – legal support of the local manufacturing project in Russia; acting as the company’s external compliance manager.
  • Philips – legal support of localisation of medical equipment production in Russia; representing the client in a product liability case.
  • Straumann – legal and regulatory assistance on circulation of medical devices, contract drafting, interactions with public authorities, tax advice, etc.
  • Servier – legal support of clinical trials in Russia (advising, drafting standard agreements and other documents for clinical trials, etc.).
  • Dr. A. & L. Schmidgall GmbH & Co KG – advising on product localisation in Russia in partnership with a local Russian manufacturer Evalar.
  • Petrovax – assisting in its CDMO project with Pfizer. Advising on advertising and promotion matters.
more less

Awards & Rankings

  • Chambers Europe 2021, Life Sciences | Band 2
  • Pravo.ru-300 2022, Life Sciences | Band 1
  • Best Lawyers 2022, Life Sciences Practice, Regulatory, Retail
  • Kommersant 2022, Healthcare
  • Kommersant 2020, Healthcare, Compliance
  • "Vsevolod Tyupa acts for both local and international pharmaceutical companies on matters including localisation, regulatory, and product acquisitions. He is also experienced in distribution as well as compliance issues." // Chambers Europe 2020
  • Vsevolod Tyupa is appreciated for his experience in commercial matters in the life sciences sphere as well as his prowess in regulatory mandates. "He is extremely responsive and client-oriented," a client says,adding: "He is ready to fight the fire with me. He is not afraid to give me a different opinion." // Chambers Europe 2021
more less


  • CMS Expert Guide to digital health apps and telemedicine, Russia chapter
  • CMS Expert Guide to vaccine compensation regimes, Russia chapter
  • CMS Expert Guide to advertising of medicines and medical devices advertising, Russia chapter 
  • Healthcare M&A, Getting the Deal Through, 2019
more less


  • 2010, Russian State University for the Humanities, PhD in Civil Law
  • 2006, Russian State University for the Humanities, Degree in Law
more less


AHK Phar­ma­ceut­ic­als and Health­care Com­mit­tee meet­ing
On 22 May 2023, Vse­volod Ty­upa will speak on the Com­puls­ory li­cens­ing at the meet­ing or­gan­ised by the Phar­ma­ceut­ic­als and Health­care Com­mit­tee of the Rus­si­an-Ger­man Cham­ber of Com­merce (AHK):For re­gis­tra­tion...
SEAM­LESS Leg­al at the 30th Phar­ma­ceut­ic­al For­um 2023
We are pleased to an­nounce that this year our firm sup­ports the 30th Phar­ma­ceut­ic­al For­um named after N.A.Semashko 2023, the flag­ship in­dustry event.Vse­volod Ty­upa, Head of Life Sci­ences & Health­care...
SEAM­LESS Leg­al ex­perts re­cog­nised by the Pravo-300 rank­ing 2023
SEAM­LESS Leg­al ex­perts have earned re­cog­ni­tion by the Pravo-300 in­di­vidu­al rank­ing re­leased on 21 Feb­ru­ary 2023. The most reput­able Rus­si­an na­tion­al rank­ing has awar­ded 12 SEAM­LESS Leg­al law­yers across...
2022: Le­gis­lat­ive out­comes for the phar­ma­ceut­ic­al and med­ic­al device in­dus­tries
Since Feb­ru­ary 2022, busi­ness in Rus­sia has been af­fected by dra­mat­ic polit­ic­al and eco­nom­ic de­vel­op­ments. Mil­it­ary ac­tion and sanc­tions have giv­en rise to lo­gist­ic­al, man­u­fac­tur­ing and repu­ta­tion­al chal­lenges...
2022: Le­gis­lat­ive de­vel­op­ments im­pact­ing the phar­ma­ceut­ic­al and med­ic­al...
Since Feb­ru­ary 2022 busi­ness in Rus­sia has been af­fected by dra­mat­ic polit­ic­al and eco­nom­ic events. Mil­it­ary ac­tion and sanc­tions have giv­en rise to lo­gist­ic­al, man­u­fac­tur­ing and repu­ta­tion­al chal­lenges...
SEAM­LESS Leg­al re­cog­nised by Pravo-300 2022
We are more than happy to share our first re­cog­ni­tion as SEAM­LESS Leg­al by the na­tion­al rank­ing Pravo.ru-300. This year SEAM­LESS Leg­al has earned 17 re­cog­ni­tions, in­clud­ing Band 1 award for the In­sur­ance...
With­draw­al and de­struc­tion of im­prop­er med­ic­al devices: new rules
31 Au­gust 2022
Rus­si­an Min­istry of In­dustry and Trade to have ac­cess to data of re­gis­tra­tion...
18 Ju­ly 2022
Pro­ced­ure in­tro­duced to trans­fer mar­ket­ing au­thor­isa­tion cer­ti­fic­ates for...
13 Ju­ly 2022
New grounds in­tro­duced for the im­port and sale of un­re­gistered medi­cines...
9 June 2022
Latest le­gis­lat­ive ini­ti­at­ives in the Life Sci­ences sec­tor im­pact­ing for­eign...
There are plans to:pro­hib­it man­u­fac­tur­ers and dis­trib­ut­ors of med­ic­al devices from leav­ing the Rus­si­an mar­ket without at least six months pri­or no­tice; an­dper­mit the sale of for­eign medi­cines in their ori­gin­al pack­ages.Exit no­tice for man­u­fac­tur­ers and dis­trib­ut­ors of med­ic­al devicesThe Rus­si­an gov­ern­ment has de­veloped and in­tro­duced to the State Duma a bill* to amend the laws “On the ba­sics of pub­lic health pro­tec­tion in the Rus­si­an Fed­er­a­tion”, “On the cir­cu­la­tion of medi­cines” and “On the con­tract sys­tem in the pro­cure­ment of goods, works, ser­vices for state and mu­ni­cip­al needs”. To re­duce the risk of un­avail­ab­il­ity of med­ic­al devices and the threat to the life and health of cit­izens (in­clud­ing due to un­timely pro­vi­sion of med­ic­al care), there are plans to pro­hib­it man­u­fac­tur­ers and dis­trib­ut­ors of med­ic­al devices from sus­pend­ing or ter­min­at­ing the pro­duc­tion of med­ic­al devices or their im­port in­to Rus­sia without giv­ing the Rus­si­an Min­istry of Health no less than six months’ no­tice.Sale of for­eign medi­cines in their ori­gin­al pack­agesIt is pro­posed to ac­cel­er­ate the pro­cess of put­ting newly-re­gistered medi­cines on the Rus­si­an mar­ket. In case of their short­age (or the risk of short­age) while sanc­tions are in place, it will be pos­sible to im­port medi­cines, put them on the mar­ket and use them in Rus­sia in the ori­gin­al (i.e. for­eign) pack­aging without a Rus­si­an trans­la­tion.The rel­ev­ant bill* has already passed first read­ing and, if ad­op­ted, will come in­to force on the date of its of­fi­cial pub­lic­a­tion. Giv­en the prompt­ness of the ad­op­tion of counter-sanc­tions in Rus­sia, the ad­op­tion of this law can be ex­pec­ted in the com­ing days.* In Rus­si­an
CMS Rus­sia earns a re­cord num­ber of re­cog­ni­tions by Best Law­yers 2022
Strong re­cog­ni­tion by the rank­ing 32 CMS Rus­sia ex­perts have been se­lec­ted for in­clu­sion in­to the 2022 edi­tion of the Best Law­yers rank­ing. In total, we have earned 74 re­cog­ni­tions by the rank­ing :Ant­on...